Search clinical trials for: AMG 552

Total 1934 results

Wyeth is now a wholly owned subsidiary of Pfizer
Amgen

Completed

Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis

Psoriasis

Belgium, France, Spain, Germany, Italy, Austria, Poland, Romania, Netherlands, Hungary
University of Washington
Amgen

Completed

Study of Aranesp to Treat Anemia in Prostate Cancer Patients.

Anemia | Prostate Cancer

United States
Heinrich-Heine University, Duesseldorf

Completed

Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis

Systemic Scleroderma | Skin Fibrosis | Hand Functionality

Germany
Heinrich-Heine University, Duesseldorf

Completed

Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus

Germany
Heinrich-Heine University, Duesseldorf

Completed

Sunscreen RV 2457C in Photoinduced CLE

Skin Lesion | Cutaneous Lupus Erythematosus | Experimental Photoinduction | Protective Sunscreen

Germany
Community Cancer Care
Amgen

Unknown

Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes

Cancer | Solid Tumor | Hematologic Malignancy

United States
Herning Hospital
Amgen

Completed

The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery

Colorectal Cancer

Denmark
University of Michigan
Amgen

Completed

Leptin and Endothelial Function

Healthy
Association Européenne de Recherche en Oncologie
Amgen; Aventis Pharmaceuticals

Completed

Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer

Node Positive Breast Cancer
Amgen

Completed

A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.

HIV Infections | Cytopenias

United States, Canada
Amgen

Completed

Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study

HIV Infections | Mycobacterium Avium-Intracellulare Infection

United States
Amgen

Completed

The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS

HIV Infections

United States
Amgen

Completed

A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex

HIV Infections | Cytopenias

United States
Glaxo Wellcome

Unknown

Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)

HIV Infections

United States
Amgen

Completed

An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)

HIV Infections

United States
Glaxo Wellcome

Completed

Safety and Effectiveness of a Combination Anti-HIV Drug Treatment

HIV Infections

United States
Celgene

Completed

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States, Australia, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Mexico, Poland, Sweden, United Kingdom, Belgium, Brazil, Denmark, Finland, Greece, Israel, Netherlands, Norway, Portugal, Spain, Turkey
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
EMD Serono Research & Development Institute, Inc.

Terminated

Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

Relapsing Multiple Sclerosis

United States, Belarus, Brazil, Bulgaria, Canada, France, Germany, Greece, India, Italy, Latvia, Lithuania, Malaysia, Moldova, Republic of, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Saudi Arabia and more
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
EMD Serono Research & Development Institute, Inc.

Terminated

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Relapsing Multiple Sclerosis

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Colombia, Croatia, Czechia, Estonia, Finland, France, Georgia, Germany, Hong Kong, Hungary, India, Israel, Italy, Korea, Republic of, M... and more
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Australia, Belgium, Chile, Colombia, Denmark, Hungary, Israel, Malaysia, New Zealand, Philippines, Poland, Russian Federation, South Africa, Sweden, Thailand, Argentina, Brazil, Canada, France, Mexico, Netherlands, Ge... and more
Otsuka Pharmaceutical Development & Commercialization...

Completed

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

Spain, United States, Italy, United Kingdom, Hungary, France, Poland, Australia, Bulgaria, Czechia, South Africa
Celgene

Recruiting

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States, Belgium, Australia, Canada, Italy, Austria, Germany, Israel, Japan, Poland, Portugal, Spain, United Kingdom, Argentina, Switzerland
Celgene

Completed

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Spain, Australia, Austria, Bulgaria, Canada, China, Colombia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Se... and more
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

United States, Spain, Hungary, Italy, Canada, Czechia, South Africa, Bulgaria, France, Poland
Celgene

Completed

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (RADIANCE)

Relapsing Multiple Sclerosis

Spain, United States, United Kingdom, Croatia, Serbia, Belarus, Hungary, Bulgaria, Poland, Italy, Ukraine, Greece, Belgium, Georgia, Bosnia and Herzegovina, Moldova, Republic of, Romania, Russian Federation, Slovakia, South Africa and more
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Argentina, Chile, Colombia and more
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events (SANTORINI)

Cardiovascular Diseases | Dyslipidemia | Hypercholesterolemia | Atherosclerotic Cardiovascular Disease

Finland, Netherlands, Spain, Belgium, Sweden, Austria, United Kingdom, Switzerland, Denmark, France, Germany, Portugal, Italy, Ireland
Boehringer Ingelheim

Completed

Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study

Hypertension

France
Boehringer Ingelheim

Completed

Spiriva Observational Study Measuring Saint George's Respiratory Questionnaire (SGRQ) in Routine Medical Practice in Central & Eastern European Region

Pulmonary Disease, Chronic Obstructive

Croatia, Poland, Romania, Russian Federation, Slovakia, Slovenia
Boehringer Ingelheim

Completed

TELMA - Observational Study in Daily Medical Practice of the Effectiveness of Telmisartan for Treatment of Hypertension in Patients With and Without Confirmed Albuminuria in Belgium

Hypertension

Belgium
Boehringer Ingelheim

Completed

Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation

Atrial Fibrillation

Japan
Boehringer Ingelheim

Completed

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Atrial Fibrillation

Germany

Search clinical trials for: AMG 552

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations